Gigamune, Inc.
San Francisco, CA Gigamune Inc.
- UEI
- KD8GTLK3VV93
- CAGE
- 7ZS06
- Primary NAICS
- Not on record
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 953 Indiana St, San Francisco, CA 94107, USA
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
About Gigamune, Inc.
Gigamune, Inc. is a biotechnology company based in San Francisco, California, focused on developing innovative gene delivery technologies, particularly using lentiviral vector platforms. The company specializes in advanced gene therapy research and development, with a proprietary technology called "GigaLenti" that enables targeted gene delivery to specific cell types. Registered in the System for Award Management (SAM.gov) since November 2017, Gigamune, Inc. has been actively pursuing federal research grants to advance cutting-edge therapeutic approaches across multiple medical domains.
The company has secured multiple significant federal grants from agencies including the National Cancer Institute, National Heart, Lung, and Blood Institute, National Institute of Arthritis and Musculoskeletal and Skin Diseases, and National Institute of Allergy and Infectious Diseases. These grants, ranging from $295,000 to $400,000, have focused on developing innovative gene therapy approaches for complex medical conditions such as Stage IV melanoma, sickle cell disease, Duchenne muscular dystrophy, and autoimmune disorders. Specific research projects have included developing lentiviral vector technologies for in vivo gene delivery to T-cells, creating targeted gene therapies for specific genetic mutations, and exploring novel approaches to cell-specific gene editing. The research consistently emphasizes reducing treatment costs, improving therapeutic efficiency, and creating more accessible treatment modalities for challenging medical conditions, with a particular focus on leveraging the company's proprietary lentiviral vector platform for precise genetic interventions.
Quick answers
What is Gigamune, Inc.'s UEI?
Gigamune, Inc.'s Unique Entity ID (UEI) in SAM.gov is KD8GTLK3VV93.
What is Gigamune, Inc.'s CAGE code?
Gigamune, Inc.'s CAGE code is 7ZS06.
Where is Gigamune, Inc. located?
Gigamune, Inc.'s physical address in SAM.gov is 953 Indiana St, San Francisco, CA 94107, USA.
Is Gigamune, Inc. registered in SAM.gov?
Yes. Gigamune, Inc.'s SAM.gov registration is active through February 24, 2027.
What is Gigamune, Inc.'s most recent federal award?
Gigamune, Inc.'s most recent federal grant award is A novel lentivector for enhanced in vivo delivery of t cell receptors for cell therapy for stage IV melanoma - project… (R44CA310160), from National Cancer Institute, on September 15, 2025.
On GovTribe
See Gigamune, Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors